Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05123950 · ClinicalTrials.gov registry record
A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 304
- Enrollment target
NCT05123950: Completed study, sponsored by Bristol-Myers Squibb.
NCT05123950 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 304 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05123950 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 304 participants
- Enrollment target
Study Summary
The purpose of this observational study is to collect real-world data that describes treatment patterns and clinical outcomes in participants with first line recurrent/metastatic squamous cell carcinoma of the head \& neck (1L R/M SCCHN).
Primary Outcome
Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head \& Neck (SCCHN)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2019-01-01 |
| Est. Completion | 2021-03-19 |
What the finished NCT05123950 record still lists
NCT05123950 is an observational study that tracks outcomes without assigning an intervention. The registered 304 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05123950 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05123950 about?
NCT05123950 is a clinical study titled "A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe". The purpose of this observational study is to collect real-world data that describes treatment patterns and clinical outcomes in participants with first line recurrent/metastatic squamous cell carcinoma of the head \& neck (1L R/M SCCHN).
What is the current status of trial NCT05123950?
This trial is currently completed. The enrollment target is 304 participants. The study started on 2019-01-01. Estimated completion is 2021-03-19.
Who is sponsoring clinical trial NCT05123950?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04750616 · 304 participants · Phase 2
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
- NCT04994717 · 304 participants · Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
- NCT06036147 · 304 participants · NA
Concussion Health Improvement Program
- NCT06096844 · 304 participants · Phase 3
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI